A Non Randomized, Open Label, Single Center Study To Evaluate The Irritation And Sensitization Potential Of Bumsuit Baby Products In Healthy Volunteer Children Using Cumulative Irritation Patch Test.

Background and Introduction

The early stages of life were recognized as critical for the healthy development of children, and proper skincare played an essential role in promoting long-term well-being. During childhood and adolescence, the skin underwent various changes; therefore, skincare products needed to be both effective and safe. Baby products, commonly used to moisturize and protect the skin, had to be carefully evaluated to ensure they did not cause irritation or sensitization, particularly in children and adolescents, whose skin was often more sensitive than that of adults.

The study participants, representing a wide range of skin types, helped determine whether the products were suitable for use in children and adolescents. This research provided essential data to confirm the safety profile of the baby products, ensuring they met safety standards and could be used confidently by parents, caregivers, and healthcare professionals.

Purpose of the Study

The purpose of the study was to evaluate the safety and suitability of baby skincare products for children and adolescents, considering their sensitive skin and varying skin types. The research aimed to confirm that these products were non-irritating, did not cause sensitization, and met established safety standards. The data obtained provided confidence to parents, caregivers, and healthcare professionals in using these products to support the healthy development and well-being of young individuals.

Results

The study was conducted over a 14-day period and included 24 healthy children aged between 5 and 18 years, all of whom completed the study. The average age of the participants was 11.5 years. Four baby care products Bumsuit Baby Cream, Lotion, Massage Oil, and Shampoo were evaluated for their irritation and sensitization potential.

Primary Endpoint (Irritation Assessment using Draize Scale): All 24 subjects showed no signs of erythema, edema, dryness, or peeling throughout the 14-day application period. No irritation reactions were observed at any time point.

Secondary Endpoint (Sensitization / Subject Self-Assessment): 100% of participants reported no burning, itching, tingling, erythema, or scaling. No delayed hypersensitivity reactions or allergic responses were observed.

Adverse Events (AEs/SAEs): No adverse events or serious adverse events were reported. No protocol deviations occurred. The compliance rate was 100%.